Also, the frequencies of CD19+CD24−CD38+ plasmablasts in the CHC-N, CHC-LC, and CHC-HCC groups were higher than that in the control group (mean, 1.7 ± 0.1, 1.8 ± 0.1, 1.8 ± 0.2 vs. 1 ± 0.2, p = 0.01, p = 0.006, p = 0.008, respectively), with no statistically significant differences among the three groups of patients. The gene discussed is CD19; the disease is hepatocellular carcinoma.